Collectively, our data suggest that GLI1 functions by activating the PI3K/AKT/GSK3β/CDK signaling pathway, leading to cell growth and drug resistance in AML cells (Fig. 7). The gene discussed is GLI1; the disease is acute myeloid leukemia.